Accelerated Corneal Collagen Crosslinking Protocols

Sponsor
Assiut University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05693740
Collaborator
(none)
40
1
2
19
2.1

Study Details

Study Description

Brief Summary

To evaluate and compare the effect of pulsed light (pl-ACXL) accelerated and continuous light accelerated (cl-ACXL) epithelium-off cross-linking in halting the progression of keratoconus.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Accelerated crosslinking (ACXL)
N/A

Detailed Description

Keratoconus (KC), which was first described in detail in 1854(1), is the most common corneal primary ectasia and is characterized by progressive bilateral (2,3) and asymmetric (4) corneal thinning and bulging outward into a cone-like shape that can severely impact patients' vision.

Keratoconus usually develops in the second and third decades of life and progresses until the fourth decade. It was thought to be a rare corneal disease. But,More recent studies suggest that it may not be as rare as was thought.(5) Despite a great deal of research, no one theory explains it all and it may be caused by a combination of things. However, Meek et al proposed that the loss of structural integrity in the KC cornea was caused by the presence of abnormal keratocytes and matrix proteins )6,7) and upregulated proteolysis triggered an unravelling of lamellae along their length and from their anchors at the limbus, with an opening of the lamellar bifurcations. This theory is supported by observations following riboflavin/UVA collagen cross-linking, where the proposed cross-linkage of the tissue increases both the resistance of the stroma to enzymatic digestion and the cohesiveness between collagen fibrils and the non-collagenous matrix. (8) Conventional CXL (CXL) with a continuous irradiation of 3 mW/cm2 for 30 min is considered safe and effective in the prevention of keratoconus progression according to different clinical trials (9,10). nevertheless, the procedure is time-consuming, lasting around 1 h, which may lead to patient discomfort and reduced physician working efficiency With evolving technical advances, commercially available UV light sources have been developed, making CXL more efficient with shorter UV exposure times, higher UV intensities, and pulsed light compared with continuous light settings (11,12)Various accelerated CXL protocols have been described and its effect on biomechanical properties on corneas stated as equal to the standard protocol(13). Yet, ex vivo studies also suggest a distinction between various accelerated CXL protocols by providing evidence for a drop in efficiency with increased UV illumination intensity while maintaining equal surface energy (14) In this study we evaluate the two types of "accelerated crosslinking".

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Single blinded Prospective, Interventional, randomized, comparative studySingle blinded Prospective, Interventional, randomized, comparative study
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Pulsed Light Versus Continuous Light Accelerated Epithelium-Off Cross-linking for Treatment of Progressive Keratoconus; a Prospective Comparative Study
Actual Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: group 1

Patients in this group will undergo pulsed light accelerated crosslinking (pl-ACXL)

Procedure: Accelerated crosslinking (ACXL)
Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.

Active Comparator: group 2

Patients in this group will undergo continuous-light accelerated crosslinking (cl-ACXL)

Procedure: Accelerated crosslinking (ACXL)
Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.

Outcome Measures

Primary Outcome Measures

  1. 1. Visual outcome measures [one year following surgery]

    Uncorrected and corrected distance visual acuity (UDVA & CDVA) using Snellen acuity chart

  2. 2. Refractive outcome measures [one year following surgery]

    Manifest refraction spherical equivalent (MRSE) using Topcon autorefractometer

  3. 3. Topographic outcome measures [one year following surgery]

    Scheimflug imaging device (Pentacam) for Diagnosis and follow up of Keratoconus after ACXL

  4. Demarcation line depth [3 months following surgery]

    Demarcation line depth is an outcome used to assess the success of CXL procedure using anterior segment ocular coherence tomography (AS-OCT)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Patients with mild to moderate progressive keratoconus with maximum keratometry value Kmax < 56.0 D, Corneal thinnest pachymetry ≥ 400 µm and Corrected distance visual acuity (CDVA) equal to or better than 20/200 Snellen's acuity.

  2. Established keratoconus progression:

Increase of 1.0D or more in the manifest cylinder Increase of 0.5D or more in the manifest refraction spherical equivalent Increase of 1.0D or more in Kmax Increase of 0.75D or more in Kmean decrease of 2% or more in central thickness

  1. Age: 18-40 y

  2. Clear cornea

Exclusion Criteria:
  1. Corneal scarring

  2. Previous corneal surgery

  3. Severe keratoconus wit non measurable refraction or Kmax ≥ 56 D or Corneal thinnest pachymetry < 400 µm

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tiba eye center Assiut Egypt 71516

Sponsors and Collaborators

  • Assiut University

Investigators

  • Principal Investigator: Mahmoud Abdel-Radi, MD, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mahmoud Abdel-Radi, Assistant professor Doctor, Assiut University
ClinicalTrials.gov Identifier:
NCT05693740
Other Study ID Numbers:
  • accelerated cross-linking
First Posted:
Jan 23, 2023
Last Update Posted:
Jan 23, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 23, 2023